Free Trial

Acumen Pharmaceuticals (ABOS) News Today

Acumen Pharmaceuticals logo
$1.03 -0.02 (-1.43%)
As of 11:06 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ABOS Latest News

Acumen Pharmaceuticals, Inc. stock logo
FY2025 EPS Estimates for ABOS Reduced by Cantor Fitzgerald
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Research analysts at Cantor Fitzgerald cut their FY2025 EPS estimates for shares of Acumen Pharmaceuticals in a note issued to investors on Thursday, May 15th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the company wil
Equities Analysts Set Expectations for ABOS FY2025 Earnings
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals (NASDAQ:ABOS) Issues Earnings Results, Beats Estimates By $0.46 EPS
Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.94) by $0.46. During the same period in the prior year, the company earned ($0.25) earnings per share.
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals (ABOS) to Release Quarterly Earnings on Tuesday
Acumen Pharmaceuticals (NASDAQ:ABOS) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 13. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-13-acumen-pharmaceuticals-inc-stock/)
Acumen Pharmaceuticals, Inc. stock logo
JPMorgan Chase & Co. Has $1.61 Million Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)
JPMorgan Chase & Co. increased its holdings in shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) by 1,387.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 937,908 shares of the company's stock after buying an
Acumen Pharmaceuticals, Inc. stock logo
Rock Springs Capital Management LP Trims Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)
Rock Springs Capital Management LP lessened its stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) by 20.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,838,916 shares of the company's stock after selling 461,143 shares during the period. Roc
Acumen Pharmaceuticals, Inc. stock logo
Franklin Resources Inc. Has $5.63 Million Holdings in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)
Franklin Resources Inc. lowered its position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) by 7.8% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,273,633 shares of the company's stock after selling 275,436 shares during the period. Frankl
Acumen Pharmaceuticals, Inc. stock logo
What is HC Wainwright's Forecast for ABOS FY2029 Earnings?
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Stock analysts at HC Wainwright issued their FY2029 earnings per share estimates for Acumen Pharmaceuticals in a research report issued to clients and investors on Friday, March 28th. HC Wainwright analyst A. Fein anticipates that the com
Acumen Pharmaceuticals, Inc. stock logo
UBS Group Lowers Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target to $4.00
UBS Group cut their price objective on Acumen Pharmaceuticals from $6.00 to $4.00 and set a "buy" rating on the stock in a research report on Friday.
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Lowered to $11.00 at HC Wainwright
HC Wainwright lowered their target price on shares of Acumen Pharmaceuticals from $15.00 to $11.00 and set a "buy" rating for the company in a research note on Friday.
Q4 2024 Acumen Pharmaceuticals Inc Earnings Call
Acumen price target lowered to $11 from $15 at H.C. Wainwright
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals (NASDAQ:ABOS) Posts Quarterly Earnings Results
Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.15).
Acumen completes enrollment of ALTITUDE-AD Phase 2 trial
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals (ABOS) Projected to Post Earnings on Tuesday
Acumen Pharmaceuticals (NASDAQ:ABOS) will be releasing earnings before the market opens on Tuesday, March 25, Financial Modeling Prep reports.
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Price Down 4% - Here's What Happened
Acumen Pharmaceuticals (NASDAQ:ABOS) Trading Down 4% - Here's Why
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Short Interest Update
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) was the target of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 1,560,000 shares, an increase of 9.1% from the December 31st total of 1,430,000 shares. Currently, 3.5% of the shares of the company are short sold. Based on an average trading volume of 276,000 shares, the short-interest ratio is currently 5.7 days.
Promising US Penny Stocks To Consider In January 2025
Acumen Pharmaceuticals, Inc. stock logo
Matt Zuga Sells 28,902 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CFO Matt Zuga sold 28,902 shares of Acumen Pharmaceuticals stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $1.72, for a total value of $49,711.44. Following the sale, the chief financial officer now directly owns 231,744 shares in the company, valued at $398,599.68. The trade was a 11.09 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Acumen Pharmaceuticals, Inc. stock logo
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) CEO Daniel Joseph Oconnell Sells 12,619 Shares
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) CEO Daniel Joseph Oconnell sold 12,619 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.59, for a total value of $20,064.21. Following the completion of the transaction, the chief executive officer now directly owns 667,488 shares of the company's stock, valued at approximately $1,061,305.92. This represents a 1.86 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Get Acumen Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.

ABOS Media Mentions By Week

ABOS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ABOS
News Sentiment

1.89

0.87

Average
Medical
News Sentiment

ABOS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ABOS Articles
This Week

1

2

ABOS Articles
Average Week

Get Acumen Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ABOS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ABOS) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners